2-[4-[bis(2-phenyl-1H-indol-3-yl)methyl]phenyl]-5-(1-methylindol-3-yl)-1,3,4-oxadiazole
C46H33N5O — CID 155552319
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[4-[bis(2-phenyl-1H-indol-3-yl)methyl]phenyl]-5-(1-methylindol-3-yl)-1,3,4-oxadiazole
2-[4-[bis(2-phenyl-1H-indol-3-yl)methyl]phenyl]-5-(1-methylindol-3-yl)-1,3,4-oxadiazole (PubChem CID 155552319) has the molecular formula C46H33N5O and a molecular weight of 671.80 g/mol. Its IUPAC name is 2-[4-[bis(2-phenyl-1H-indol-3-yl)methyl]phenyl]-5-(1-methylindol-3-yl)-1,3,4-oxadiazole.
Molecular Properties
| Compound Name | 2-[4-[bis(2-phenyl-1H-indol-3-yl)methyl]phenyl]-5-(1-methylindol-3-yl)-1,3,4-oxadiazole |
|---|---|
| PubChem CID | 155552319 |
| Molecular Formula | C46H33N5O |
| Molecular Weight | 671.80 g/mol |
| Exact Mass | 671.27 |
| IUPAC Name | 2-[4-[bis(2-phenyl-1H-indol-3-yl)methyl]phenyl]-5-(1-methylindol-3-yl)-1,3,4-oxadiazole |
| SMILES | Cn1cc(-c2nnc(-c3ccc(C(c4c(-c5ccccc5)[nH]c5ccccc45)c4c(-c5ccccc5)[nH]c5ccccc45)cc3)o2)c2ccccc21 |
| InChI | InChI=1S/C46H33N5O/c1-51-28-36(33-18-10-13-23-39(33)51)46-50-49-45(52-46)32-26-24-29(25-27-32)40(41-34-19-8-11-21-37(34)47-43(41)30-14-4-2-5-15-30)42-35-20-9-12-22-38(35)48-44(42)31-16-6-3-7-17-31/h2-28,40,47-48H,1H3 |
| InChIKey | OAUPBQFOSARFQJ-UHFFFAOYSA-N |
| XLogP | 11.37 |
| TPSA | 75.43 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 52 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 671.80 |
| LogP ≤ 5 | 11.37 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155552319 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.